Business Model Breakdown
How Journey Medical Corp Makes Money
DERM
Market Cap
$165M
Annual Revenue
$139M
Profit Margin
-14.8%
Employees
41
The Short Version
Journey Medical Corp (DERM) is a commercial-stage pharmaceutical company focused on acquiring, developing, and commercializing innovative dermatology products. It makes money by selling prescription medications for various skin conditions, primarily through its existing portfolio like Emrosi® for rosacea ($6.3M revenue in Q1 2026), and is heavily investing in its pipeline drug, DFD-29, which is awaiting FDA approval for rosacea and is expected to be a major revenue driver.
Where the Revenue Comes From
Sales of prescription dermatology products (e.g., Emrosi® contributing $6.3M in Q1 2026)
Who buys: Dermatologists, general practitioners, and patients primarily within the United States.
Why It Works (Competitive Advantages)
- ✔Potential for a differentiated therapeutic profile for DFD-29 in the rosacea market.
- ✔Established commercial infrastructure and expertise in dermatology products through its existing portfolio.
Economic Moat: None (Intangible Assets/IP (potential future patent protection for DFD-29 if approved))
What Our Analysis Says
DVR Score as of June 10, 2026
Journey Medical (DERM) maintains its high-risk, high-reward profile, primarily driven by the upcoming PDUFA decision for DFD-29 in Q3 2026. The Q1 2026 earnings report showed positive signs with a revenue beat ($15.96M vs. $15.47M consensus), 21% YoY growth, narrowing losses (EPS $(0.08)$ vs $(0.18)$ YoY), and positive Adjusted EBITDA of $0.62M. Cash and equivalents also increased to $27.22M, providing a longer runway. While competitive and regulatory risks remain paramount, the substantial rosacea market opportunity and DFD-29's differentiated profile, coupled with improving financial metrics, underscore the transformative potential if regulatory success and commercialization are achieved. The score reflects a strong potential upside tempered by significant pipeline dependency.